



**Human Vaccines & Immunotherapeutics** 

ISSN: (Print) (Online) Journal homepage: www.informahealthcare.com/journals/khvi20

# Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis

Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou & Florence Galtier

**To cite this article:** Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou & Florence Galtier (2021) Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis, Human Vaccines & Immunotherapeutics, 17:10, 3771-3783, DOI: <u>10.1080/21645515.2021.1932214</u>

To link to this article: https://doi.org/10.1080/21645515.2021.1932214

+	View supplementary material 🕝	Published online: 16 Jul 2021.
	Submit your article to this journal 🗹	Article views: 1205
Q	View related articles 🕝	Uiew Crossmark data 🗗
ආ	Citing articles: 3 View citing articles 🗹	

#### REVIEW

Check for updates

Taylor & Francis

Taylor & Francis Group

# Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis

Alhassane Diallo D<sup>a\*</sup>, Miguel Carlos-Bolumbu<sup>b\*</sup>, Minerva Cervantes-Gonzalez<sup>c</sup>, Veronika Wozniak<sup>d</sup>, Mamadou Hassimiou Diallo<sup>e</sup>, Boubacar Djelo Diallo<sup>f</sup>, Alexandre Delamou<sup>g</sup>, and Florence Galtier<sup>h</sup>

<sup>a</sup>CIC-EC 1425, Department of Epidemiology, Biostatistics, Clinical Research, AP-HP Hospital Bichat, University of Paris Diderot, Paris, France; <sup>b</sup>Département d'Urgence-Réanimation, Centre Hospitalier Sud-Essones CHSE, Paris, France; <sup>c</sup>CIC-EC 1425, Department of Epidemiology, Biostatistics, Clinical Research, AP-HP Hospital Bichat, Paris, France; <sup>d</sup>Faculty of Medicine, University Paris Diderot, Paris, France; <sup>e</sup>Centre population et développement, Institut de recherche pour le développement, Université Paris Descartes, Paris, France; <sup>f</sup>Faculté des Sciences et Techniques de la Santé, Université Gamal Abdel Nasser de Conakry, Service de Pneumo-Phtisiologie, CHU Conakry, Hôpital National Ignace Deen de Conakry, Conakry, Guinea; <sup>g</sup>Gamal Abdel Nasser University, Conakry, Guinea; <sup>h</sup>INSERM, CIC 1411, CHU of Montpellier, Saint Eloi Hospital, Montpellier, France

#### ABSTRACT

Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety. A total of 21 randomized controlled trial, evaluating seven different vaccines with different doses, and 5,275 participants were analyzed. The rVSVΔG-ZEBOV-GP ( $2 \times 10^{7}$ ) vaccine was more immunogenic (*P*-score 0.80). For pain, rVSVΔG-ZEBOV-GP ( $\leq 10^{5}$ ) had few events (*P*-score 0.90). For fatigue and headache, the DNA-EBOV ( $\leq 4$  mg) was the best one with *P*-scores of 0.94 and 0.87, respectively. For myalgia, the ChAd3 (10<sup>10</sup>) had a lower risk (*P*-score 0.94). For fever, the Ad5.ZEBOV ( $\leq 8 \times 10^{10}$ ) was the best one (*P*-score 0.80). The best vaccine to be used to stop future outbreak of Ebola is the rVSVDG-ZEBOV-GP vaccine at dose of  $2 \times 10^{7}$  PFU.

#### **ARTICLE HISTORY**

Received 10 February 2021 Revised 2 May 2021 Accepted 15 May 2021

#### **KEYWORDS**

Ebolavirus; network metaanalysis; vaccine; healthy volunteer

# Introduction

According to the World Health Organization (WHO), the 2013–16 West African Ebola Virus epidemic (EBOV) was the largest and deadliest in history with more than 28,600 confirmed infections and over 11,300 deaths.<sup>1,2</sup>

Since this epidemic, many efforts have been made to accelerate the development of candidate vaccines against Ebola virus disease (EVD). To date, only the recombinant replication competent vesicular stomatitis virus-based vaccine expressing the glycoprotein of a Zaire Ebolavirus licensed as ERVEBO<sup>®</sup> (rVSV $\Delta$ G-ZEBOV-GP) at a dose of 2  $\times$  10<sup>7</sup> plaque-forming unit (PFU) has been proven to have a high efficacy and effectiveness to prevent EVD in contacts and contacts of contacts of recently confirmed cases in Guinea (Conakry) and Sierra-Leonne.<sup>3</sup> However, some safety concerns related to this vaccine, in particular one anaphylaxis,<sup>3</sup> four arthralgia,<sup>4</sup> and 19 arthritis<sup>4</sup> have been reported. The need for an alternative vaccine is all the more crucial since vaccination not only prevents infection but also limits its severity: in a recent therapeutic study including affected patients during the 2018 EVD outbreak in the Democratic Republic of Congo (RDC), those who had been vaccinated had less severe clinical forms at baseline.<sup>5</sup>

Many other vaccines have been tested in healthy volunteers, with promising results on both safety and immunogenicity, but with very different protocols (design, dose administered or timing of evaluation).<sup>6,7</sup> With the multiplicity of clinical trials against EVD, data on an effective vaccine with the optimal dose are needed to control any future outbreak like the one that happened in West Africa or more recently in the Democratic Republic of Congo.<sup>5</sup>

To our knowledge, no systematic review or meta-analysis has been conducted to summarize published data on candidate vaccines from clinical trials studies in healthy adults to identify the most effective in terms of safety and immunogenicity. We therefore conducted a network meta-analysis (NMA) to compare and rank candidate vaccines tested in healthy adults in terms of safety and immunogenicity to prevent EVD.

#### Methods

#### Search strategy and selection criteria

We searched through MEDLINE, EMBASE, and Cochrane library (CENTRAL) for randomized controlled trials (RCTs) that investigated Ebola virus vaccine safety and immunogenicity in healthy adults. Despite the extensively safety and immunogenicity databases mainly for rVSV and Ad26 or MVA vaccines, we choose to restrict our search to the RCTs which gives the highest evidence level. The search was restricted to any phase trials (1, 2, and 3) conducted in human, and published in English before November 30, 2020. For studies that involve prime/boost, only data from

CONTACT Alhassane Diallo 🖾 alhassane.diallo@inserm.fr 🗈 CIC-EC 1425, Department of Epidemiology, Biostatistics, Clinical Research, AP-HP Hospital Bichat, University of Paris Diderot, Paris, France

\*These authors contributed equally to this work

Supplemental data for this article can be accessed on the publisher's website at https://doi.org/10.1080/21645515.2021.1932214.
2021 Taylor & Francis Group, LLC

the prime vaccination evaluated 28 days was considered. Studies in which participant were nonrandomly allocated to receive Ebola virus vaccine, or in which a combination of vaccines was used, or in which participants were aged less than 18 years, or in which information on outcomes was lacking were excluded. Using the search terms listed in the Methods in the Supplement, two authors (ADi and VW) identified all relevant studies, then independently reviewed their full texts, and in case of disagreement, differences were resolved through the arbitration by another author (MCB). Extracted data included: first author name and year of publication, country, RCTs design, study follow-up, age (range), proportion of men participants, vaccine type and dosing information, sample size, proportion or number of participants with seroconversion or seroresponse and adverse events, and study sponsorship (Government and/or Industry). The study protocol was registered in the International Register of Systematic Reviews (PROSPERO), number CRD42018109473.

#### Outcomes

The primary outcome was immunogenicity assessed by either the seroconversion rate-proportion of participants who showed at least a four-fold increase in antibody titer for enzyme-linked immunosorbent assay (ELISA) 28 days after vaccination-, or seroresponse rate - proportion of participants who had a protective titer (seropositivity) measured by ELISA titer above a prespecified threshold 28 days after vaccination. Because of the variability of the method used to assess immunogenicity of Ebola virus vaccine, we considered only seroconversion or seroresponse rates based on ELISA titers at 28 days. In case both seroconversion and seroresponse were available in a study, only the seroconversion rate was used, as it is less sensitive to baseline status. Secondary outcomes were the most common Adverse Events (AEs) occurring within the first 14 days post vaccination, and recorded according to the Common Terminology Criteria for Adverse Events.<sup>8</sup> The two categories of Adverse Events outcomes considered in this network meta-analysis were the solicited local reaction, mainly injection-site pain, and the systematic reactions including fatigue, headache, fever, and myalgia. Because of the limited number of recorded Grade 3 adverse events, we subtracted them from the analysis, leaving only the reported mild (Grade 1) and moderate (Grade 2), which were analyzed together as a single outcome.

# Data analysis

The original clinical trials were described using table of study characteristics and forest plot. The Cochrane risk of bias tools<sup>9</sup> and Revman version 5.3 were used to assess the risk of bias and to generate the corresponding figures. We opted for a frequentist approach to compare safety and immunogenicity between candidates vaccine using a random-effects network meta-analysis (NMA) for binary endpoint. Summary estimates were reported as odds ratio (OR) with their reported 95% confidence intervals. For immunogenicity, beneficial vaccine effects are described by ORs > 1, while for the safety outcomes, beneficial vaccine effects are described by ORs < 1. Because of the large variety of tested

dose by vaccine, we grouped them in 12 categories ( $\leq 4$  mg,  $8 \text{ mg}, \le 10^5, 10^6, 10^7, 2 \times 10^7, 5 \times 10^7, 10^8, 10^{10}, \le 8 \times 10^{10}, 10^{11},$ and  $1.6 \times 10^{11}$ ), then we considered these categories as separate nodes in the network. For each dose group, we distinguished between placebo, Ad26.ZEBOV, Ad5-EBOV, Chad3-ZEBOV, DNA-EBO, MVA-BN-Filo, rVSVN4CT1-EBOVGP1, and rVSV $\Delta$ G-ZEBOV-GP, thereby giving 18 different groups of vaccine to compare. Full names of these acronyms are defined in appendix (page 6). To display the relative efficacy on immunogenicity and adverse events outcomes of all available pairwise comparisons between vaccine, league tables were used. A P-score ranging from 0 (worst vaccine) to 1 (best vaccine) was computed for each vaccine, then the vaccine with the highest P-score was selected as the preferred vaccine regimen for each considered outcome. Heterogeneity and inconsistency were quantified using the global Q test proposed by Rucker.<sup>10</sup> The Q statistic is the sum of statistic for heterogeneity, which represent the proportion of the total variation in study estimates (within-designs), and a statistic for inconsistency (between-designs), which represents the variability of the vaccines effect between direct and indirect comparisons at the meta-analytic level.<sup>10</sup> To visualize and identify nodes of single-design inconsistency, we used a network heat plot. Consistency between direct and indirect comparisons was checked using the so-called node-splitting. We conducted three sensitivity analyses, first to assess sponsorship bias by excluding studies sponsored by industrial companies, second to test for differences between health care system by excluding studies conducted in Africa, and finally to assess the impact of the risk of bias by excluding studies with a moderate risk of bias. No subgroup analysis was performed. All analyses were performed using R package 'netmeta';<sup>10</sup> P-values <.05 were considered significant for the difference between vaccines.

# Results

#### **Included studies**

The initial search through all database identified 382 citations, of which 120 were screened by title and abstract after removing duplicates. Of the 29 full-text citations reviewed, 21 RCTs<sup>4,11-31</sup> that met the inclusion criteria were finally included in the quantitative network meta-analysis (Figure 1). These RCTs were published from 2006 to 2020, 13 in high impact factor journals (9 in The Lancet, 3 in The NEJM, 1 in JAMA). Fifteen were phase 1 trial, 2 were phase 3 trials, 17 were blinded, 15 were conducted in high-income countries, and 18 were sponsored by Government institutions. For the phase 3 study conducted in Sierra-Leonne, we included only the participants involved in the safety substudy (n = 449). Together, these 21 RCTs included 5,275healthy volunteers aged 18 and 65 years, of whom 2,983 (56.5%) were male. A total of 62 comparisons for immunogenicity (Figure 2) were investigated in a follow-up time ranging from 12 weeks to 12 months (Table 1).

The methodological quality of the included RCTs is shown in Figure 3. Overall, the risk of bias was low in nine RCTs, and moderate in the others (Figure S1 and Table S1 in the Supplement). A higher risk of attrition bias (incomplete outcome data), detection bias (blinding outcome assessment), and




Figure 1. PRISMA flowchart of studies selected for meta-analysis of RCT Ebola vaccine.

performance bias (blinding participants and personnel) occurred in 4, 2, and 2 of 21 RCTs respectively.


#### Immunogenicity

Of the 5,275 participants, 3,110 (59.0%) had seroconverted at 28-days post-vaccination. Figure 2 shows the network for immunogenicity captured by the immunogenicity of candidate vaccine against Ebola virus. All vaccines were significantly more immunogenic than placebo (Figure 4), and the corresponding pairwise comparisons are summarized in the Supplement (Table S2). The vaccine with the highest probability of giving the highest seroconversion rate was the recombinant vesicular virus-based vaccine expressing a Zaire Ebola virus glycoprotein (rVSV $\Delta$ G-ZEBOV-GP) at the dose of 2 × 10<sup>7</sup> PFU, with a P-score of 0.80, and an OR over Placebo of 259.1 (95% CI 134.4-449.5). Among vaccines, we found that the MVA-BN-Filo at dose of  $10^8$  TCID<sub>50</sub> (50% tissue culture infectious doses) was significantly less immunogenic. Compared to the latter, patients in the adenovirus type-26 vector-based Ebola group (Ad26-ZEBOV) at doses of  $5 \times 10^{10}$  VP had 24 times more likely to be immunized 28-days after vaccination (Figure S2).

Only 2 others pairwise comparisons were significant: the rVSV $\Delta$ G-ZEBOV-GP vaccine with doses of 2 × 10<sup>7</sup> PFU (OR 2.77, 1.24–6.21) and 10<sup>6</sup> PFU (2.34, 1.08–5.06) conferred more immunogenicity than lower dose ( $\leq 5 \times 10^5$  PFU). Likewise, no significant differences were found between direct and indirect treatment estimates comparisons or evidence of publication bias according to the comparison-adjusted funnel plot (Figure S3 in the Supplement).

# Safety

A total of 9,194 adverse events were reported between sevenand 14-days post-vaccination, in which 127 (1.4%) were severe (SAEs). The ratio of adverse events per participant was 1.7 (9,194/5,275) meaning that on average each participant reported at least more than one adverse reaction (local or systemic). The most commonly reported mild-to-moderate AEs were injection-site pain (1,544 AEs), headache (1,578), fatigue (1,007), myalgia (810), and fever (1,145). Likewise, among the 127 severe reported adverse reactions, the most prevalent were headache (33), fever (32), fatigue (20), chills (15), and myalgia (13).



**Figure 2.** Network graph of eligible Ebola vaccines comparisons for immunogenicity. Line width is proportional to the number of trials comparing every pair of vaccine. The size of the circle is proportional to the number of participants assigned to receive the vaccine. **rVSVZGP (10e5 or lower), (10e6), (10e7), (2dose10e7), (5dose10e7), and (10e8)** were the recombinant replication competent vesicular stomatitis virus-based vaccine expressing the glycoprotein of a Zaire Ebolavirus (rVSVAG-ZEBOV-GP) at doses of  $\leq 10^5$  plaque-forming unit (PFU),  $10^6$  PFU,  $10^7$  PFU,  $2 \times 10^7$  PFU,  $5 \times 10^7$  PFU, and  $10^8$  PFU; **ChAd3 (10e10) and (10e11)** were the replication-defective chimpanzee adenovirus 3 vector expressing Zaire-Ebola virus glycoprotein (ChAd3-EBO-Z) at doses of  $10^{10}$  viral particles (VP) and  $10^{11}$  VP; **MVA (10e8)** was the modified vaccina Ankara (MVA) expressing Zaire Ebola virus glycoprotein and other filovirus antigens (MVA-BN-Filo) at doses of  $1 \times 10^8$  50% tissue culture infectious doses (TCID<sub>50</sub>); **Ad5 (8dose10e10 or lower) and (1.6dose10e11)** were the adenovirus type-5 vector-based Ebola vaccine (Ad26-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and  $1.6 \times 10^{11}$  VP; **Ad26 (5dose10e10)** was the adenovirus type-26 vector-based Ebola vaccine (Ad26-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and **DNAEBO (4 mg or lower) and 8 mg** were the Ebola virus glycoprotein DNA vaccine (EBODNA012-00-VP) at doses of 4 mg/ml and 8 mg/ml; **rVSVN4CT1 (10e5 or lower), and (10e6)** were the recombinant replication competent vesicular stomatitis virus-based vaccine expressing HIV-1 gag and glycoprotein of Ebolavirus (rVSVN4CT1-EBOVGP1) at doses of  $2.5 \times 10^4$  PFU,  $2.5 \times 10^5$  PFU, and  $2 \times 10^6$  PFU.

rVSV∆G-ZEBOV-GP (≤10<sup>5</sup>) was associated with a 90% lower probability of injection-site pain (*P*-score 0.90). Importantly, the lower dose (≤ 10<sup>5</sup> PFU) of the rVSV∆G-ZEBOV-GP vaccine induced a lower risk of pain compared to the same vaccine at higher doses. The corresponding risk reduction of pain were 78% (0.22, 0.08–0.60) for 10<sup>6</sup> PFU, 85% (0.15, 0.06–0.41) for 2 × 10<sup>7</sup> PFU, 88% (0.12, 0.04–0.40) for 10<sup>8</sup> PFU, 93% (0.07, 0.01–0.76) for 10<sup>7</sup> PFU, and 93% (0.07, 0.02–0.33) for 5 × 10<sup>7</sup> PFU. In addition, the lower dose (10<sup>5</sup> PFU) of the rVSV∆G-ZEBOV-GP vaccine reduced by 83% (0.17, 0.04–0.67) the risk of injection site pain when compared to the Ad5 (1.6 × 10<sup>11</sup>) vaccine (Table S3 in the Supplement).

For fatigue, the network meta-analysis was conducted in 19 RCTs involving 17 groups of vaccines and 59 pairwise comparisons. We found that the DNA-EBOV vaccine at dose of  $\leq 4$  mg was associated with less fatigue symptoms with a higher probability (*P*-score 0.94) of being the best one. The fatigue risk reduction for DNA-EBOV vaccine ( $\leq 4$  mg) was 82% (0.18, 0.03–0.95) compared to the ChAd3 vaccine at dose of 10<sup>11</sup>, 84% (0.16, 0.03–0.80) for 10<sup>6</sup> PFU, 84% (0.16, 0.03–0.73) for 2 × 10<sup>7</sup> PFU, and 88% (0.12, 0.02–0.61) for 10<sup>8</sup> PFU. Compared to placebo, the highest dose of ChAd3 vaccine (10<sup>11</sup>) multiplied by 2.76 (1.26–6.03) the risk of fatigue (Figure 5). The corresponding increased risk of fatigue compared with rVSV $\Delta$ G-ZEBOV-GP vaccine were 3.12 (1.62–6.00) for 10<sup>6</sup> PFU, 3.19 (1.98–5.15) for 2 × 10<sup>7</sup> PFU, and 4.18 (2.12–8.02) for 10<sup>8</sup> PFU. In addition, a higher dose (10<sup>6</sup> PFU) of rVSVN4CT1-EBOVGP1 vaccine was significantly associated with an increased risk of fatigue compared with other vaccines, except for the rVSV $\Delta$ G-ZEBOV-GP vaccine at dose of 10<sup>7</sup> PFU (0.05, 0.00–1.42) and 10<sup>8</sup> PFU (0.06, 0.00–1.29) (Table S4 in the Supplement). Finally, a lower dose ( $\leq 10^5$ ) of rVSV $\Delta$ G-ZEBOV-GP vaccine was associated with 57% (0.43, 0.20–0.91) risk reduction of fatigue compared with a higher dose (10<sup>8</sup> PFU).

For headache, pairwise comparisons were performed in all RCTs. As for fatigue, the DNA-EBOV vaccine at dose of  $\leq 4 \text{ mg}$ gave the best results (P-score 0.87). A significantly lower risk of headache was seen in 39 of the 63 indirect comparisons (Table S5 in the Supplement). The specific risk reductions of headache for DNA-EBOV vaccine (≤ 4 mg) were 80% (0.20, 0.04–0.97) and 99% (0.01, 0.00-0.20) compared to the ChAd3 vaccine at dose of 10<sup>11</sup> and to the rVSVN4CT1-EBOVGP1 at dose of 10<sup>6</sup> PFU, respectively. The corresponding risk reductions of headache compared to the rVSVAG-ZEBOV-GP vaccine were 77% (0.23, 0.07-0.79) for 10<sup>6</sup> PFU, 77% (0.23, 0.07-0.75) for 2 × 10<sup>7</sup> PFU, 78% (0.22, 0.07-0.76) for 10<sup>8</sup> PFU, and 82% (0.18, 0.03--0.97) for  $10^7$  PFU. In addition, when compared with rVSV $\Delta$ G-ZEBOV-GP at dose of 2  $\times$  10<sup>7</sup> PFU, the risk of headache was reduced by 67% (0.33, 0.12-0.94) for MVA-BN-Filo  $(10^8 \text{ TCID}_{50})$ , 62% (0.38, 0.19–0.78) for Ad5-EBOV ( $\leq$  $8 \times 10^{10}$ ), 60% (0.40, 0.25–0.64) for rVSV $\Delta$ G-ZEBOV-GP ( $\leq$  $10^5$ ), and 60% (0.40, 0.25–0.64) for Ad5-EBOV (1.6 ×  $10^{11}$ ). The corresponding risk reduction of headache compared with rVSV $\Delta$ G-ZEBOV-GP at dose of 10<sup>6</sup> and 10<sup>8</sup> PFU were shown

s vaccination.
virus
f Ebola
of
safety
and
imunogenicity
e im
the
investigating
trials
uded t
inclue
÷
s of
1. Characteristics
Table

Sponsorship	NR	NR	Government and Industry	Wellcome Trust through WHO	Government	Government	Government	Government	Government and Industry ( <i>Continued</i> )
Main outcomes at 14 days for Safety and 28 days for Immunogenicity measured by ELISA	ELISA positive response rate to GP [Z], pain, myalgia, headache, fever, myalgia, malaise, nausea, induration, skin discoloration	ELISA positive response rate to GP [Z], pain, myalgia, headache, fever, myalgia, malaise, chills, nausea, redness, swellind	response, pain, e, fever, myalgia, cough, diarrhea, ss, swelling, joint	ropositivity rate, local pain, fatigue, headache, myalgia,	Proportion of positive response by ELISA ( titer of 30 or higher, pain, tenderness, swelling, redness, chills, aching joints, fatigue, headache, fever, nausea, muscle aches	Seropositivity rate measured by ELISA of Government 50 or more, erythema, swelling/ induration, pain, fever, chills, myalgia, headache, fatigue, gastro-intestinal symptoms, oral vesicle, arthralgia, arthritis	of positive ELISA GP [Z] e or responses of more than e value, pain and tenderness, tigue, myalgia, arthralgia,	A GP [Z] erythema, chills, fatigue /er, nausea, abdominal	Percentages of vaccine responders pair, currents, minute seponders assessed by ELISA, pain, erythema, warmth, pruritus, swelling, induration, fatigue, headache, fever, nausea, myalgia, chills, rash, nausea, pyrexia, arthralgia, vomiting
Dosing Information	EBODNA012-00-VP (2 mg), EBODNA012- 00-VP (4 mg), EBODNA012-00-VP (8 mg), placebo	rAd5.ZEBOV.GP (2 $\times$ 10 <sup>9</sup> VP), rAd5.SBOV. GP (2 $\times$ 10 <sup>10</sup> VP), placebo	rAd5.ZEBOV.GP high dose (1.6 × 10 <sup>11</sup> PV), rAd5.ZEBOV.GP low dose (4 × 10 <sup>10</sup> PV), placebo	rVSVAG-ZEBOV- rVSVAG-ZEBOV-GP (3 × 10 <sup>5</sup> PFU), GP rVSVAG -ZEBOV-GP (1 × 10 <sup>7</sup> PFU), rVSVAG -ZEBOV-GP (5 × 10 <sup>7</sup> PFU), nlaceho	EBO vaccine (4 mg), placebo	rVSVΔG -ZEBOV-GP (1 × 10 <sup>7</sup> PFU), rVSVΔG -ZEBOV-GP (5 × 10 <sup>7</sup> PFU), placebo	ChAd3-EBO-Z (1 × 10 <sup>10</sup> VP), ChAd3-EBO -Z (1 × 10 <sup>11</sup> VP), ChAd3-EBO-Z (2.5 × 10 <sup>10</sup> VP), ChAd3-EBO-Z (5 × 10 <sup>10</sup> VP),	ChAd3-EBO-Z (2.5 × 10 <sup>10</sup> VP), ChAd3- EBO-Z (5 × 10 <sup>10</sup> VP), placebo	Ad26.ZEBOV (5 $\times$ 10 <sup>10</sup> VP), MVA-BN-Filo (1 $\times$ 10 <sup>8</sup> TCID <sub>50</sub> ), placebo
ر Vaccine type	DNA	rAd5.ZEBOV-GP	rAd5.ZEBOV-GP	rVSVΔG-ZEBOV- GP	DNA	rVSV-ZEBOV-GP	ChAd3-EBO-Z	ChAd3-EBO-Z	Ad26.ZEBOV, MVA-BN-Filo
Proportion of men participants	67%	53%	49%	54%	82%	61%	45% (USA), 80% (Mali)	49%	36%
Follow-up	12 months	48 weeks	4 weeks	12 weeks	24 months	6 months	5 months	6 months	8 months
Age (years)	18-44	18–50	18–60	18–65	18–50	18-65	18–65	18–65	18-50
Design	RCT, phase 1, double-blind	RCT, phase 1, double-blind	RCT, phase 1, double-blind	RCT, phase 1–2, double-blind	RCT, phase 1b, double-blind	RCT, phase 1, double-blind	RCT, phase 1, double-blind	RCT, phase 1–2a, double-blind	RCT, phase 1, observer-blind
Country	USA	USA	China	Switzerland (Geneva)	Uganda (Kampala)	Switzerland (Geneva)	USA, Mali (groups 3B and 3 C)	Switzerland (Lauzanne)	ž
Study	Martin et al. <sup>10</sup>	Ledgerwood et al. <sup>11</sup>	Zhu et al. <sup>12</sup>	Huttner et al. <sup>13</sup>	Kibuuka et al. <sup>14</sup>	Agnandji et al. <sup>a 15</sup>	D Tapia et al. <sup>b,d 16</sup>	De Santis et al. <sup>17</sup>	Milligan et al. <sup>c. d 18</sup>


Sponsorship	Government	Government	Government and Industry	Government	Government	Government	Government (Continued)
Main outcomes at 14 days for Safety and 28 days for Immunogenicity measured by ELISA	Seroconversion for IgG ELISA as four times or more than baseline titer, abdominal pain, diarrhea, fatigue, shivering or chills, headache, joint aches and pain, joint swelling or tenderness, vomiting, myalgia, nausea, fever, sweats arm pain, local tenderness	Seropositivity rates as percentage of participants having arbitrary ELISA units (AEU) > a cutoff per vaccine, Seroconversion rates as % of converted in each group, pain, swelling, chills, fatigue, headache, fever, nausea, myalgia, arthralgia, mouth ulcer, skin lesion, blister, malari, rhinitis, cough, gastro- intestinal symmetoms	Number of responders assessed by neutralizing antibody titer against Ad5 > 1:200, induration swelling, rash, fever, headache, fatigue, cough, pain, joint pain, muscle pain, throat	Ро	Seroconversion as at least 4-fold Seroconversion as at least 4-fold increase from ELISA baseline, pain, abdominal pain, chills, arthralgia, fever, diaphoresis, diarrhea, fatigue, headache mvalria, nausaa	Number of responders assessed by neutralizing antibody titer against Ad5 > 1:200, induration swelling, itch, fever, headche, fatigue, cough, pain, joint pain, muscle pain, throat	Positive response for ELISA was a titer of Government 50 or more. Seroconversion was a quadrupling of the titer over the baseline value, abdominal pain, site pain, headache, myalgia, nausea, fever, fatigue, chills, arthralgia, diaphoresis, diarrhea
Dosing Information	<pre>MSVΔG-ZEBOV-GP (3 × 10<sup>3</sup> PFU), rVSV- ZEBOV-GP (3 × 10<sup>4</sup> PFU), rVSVΔG-ZEBOV-GP (3 × 10<sup>5</sup> PFU), rVSVΔG-ZEBOV-GP (3 × 10<sup>5</sup> PFU), rVSVΔG-ZEBOV-GP (9 × 10<sup>6</sup> PFU), rVSVΔG-ZEBOV-GP (2 × 10<sup>7</sup> PFU), rVSVΔG-ZEBOV-GP (1 × 10<sup>8</sup> PFU), nI2zebo</pre>	NSVAG -ZEBOV-GP (3 × 10 <sup>3</sup> PFU), rVSVΔG -ZEBOV-GP (3 × 10 <sup>4</sup> PFU), rVSVΔG -ZEBOV-GP (3 × 10 <sup>5</sup> PFU), rVSVΔG -ZEBOV-GP (3 × 10 <sup>6</sup> PFU), rVSVΔG -ZEBOV-GP (2 × 10 <sup>7</sup> PFU), placebo	rAd5.ZEBOV-GP (1.6 × 10 <sup>11</sup> VP), rAd5. ZEBOV-GP (8 × 10 <sup>10</sup> VP), placebo	ChAd3-EBO-Z (1 $\times$ 10 <sup>11</sup> VP), rVSV-ZEBOV -GP (2 $\times$ 10 <sup>7</sup> VP), placebo	rVSVΔG-ZEBOV- rVSVΔG-ZEBOV-GP (1 × 10 <sup>5</sup> PFU), GP rVSVΔG-ZEBOV-GP (5 × 10 <sup>5</sup> PFU), rVSVΔG-ZEBOV-GP (3 × 10 <sup>6</sup> PFU), placebo	rAd5.ZEBOV-GP (1.6 × 10 <sup>11</sup> VP), rAd5. ZEBOV (4 × 10 <sup>10</sup> VP), placebo	rVSVΔG-ZEBOV- rVSVΔG-ZEBOV-GP (3 × 10 <sup>6</sup> PFU), GP rVSVΔG-ZEBOV-GP (2 × 10 <sup>7</sup> PFU), rVSVΔG-ZEBOV-GP (1 × 10 <sup>8</sup> PFU), placebo
ר Vaccine type	rVSVΔG-ZEBOV- GP	rvsv∆G-ZEBOV- GP	rAd5.ZEBOV-GP	ChAd3-EBO-Z, rVSV-ZEBOV- GP	rVSV∆G-ZEBOV- GP	rAd5.ZEBOV-GP	rVSVΔG-ZEBOV- GP
Proportion of men participants	53%	82%	54%	63%	42%	48%	71%
Follow-up	12 months	6 months	6 months	12 months	6 months	6 months	8.5 months
Age (years)	18–61	18–50	18–50	18 or more	18–65	18–60	18–50
Design	RCT, phase 1, double-blind	RCT, phase 1, open-label	RCT, phase 2, double-blind	RCT, phase 2, double-blind	RCT, phase 1, observer-blind	RCT, phase 1, double-blind	RCT, phase 1, observer-blind
Country	USA	Gabon (Lambaréné)	Sierra Leone	Liberia	Canada	China	USA
Study	Heppner et al. <sup>19</sup>	Agnandji et al. <sup>4</sup>	Zhu et al <sup>20</sup>	Kennedy et al. <sup>21</sup>	Elsherif et al. <sup>22</sup>	Li et al. <sup>d 23</sup>	Regules et al. <sup>24</sup>

Table 1. (Continued).

তি	
Ð	
2	
÷	
Ξ	
0	
9	
•	
÷	
e 1.	
·	
<u>e</u>	

79%   Ad26.ZEBOV, MVA-BN-Filo   Ad26.ZEBOV, (1 × 10° TCID <sub>50</sub> )   NMA-BN-Filo   Industry rash pyrexia, puntus (generalized) rash pyrexia, puntus (generalized)   Government Government (Kikwit), injection site pain, injection site pruritus, injection site warmth, hadache, fatigue, fever, myalgia, arthalgia, chills, nauses, vomiting, arthalgia, puntus (generalized)   Government and site pruritus, injection site warmth, hudustry hadache, fatigue, fever, myalgia, arthalgia, puntus (generalized)   Moustry and site pruritus, injection site warmth, hudustry arthalgia, chills, nauses, vomiting, arthalgia, pain, chills, fatigue intermediate dose 2.5 × 10° high dose 1.8/10° high dose 1.8/10° high dose 1.8/10° high dose 1.8/10°   Moustry arthalgia, pain, chills, fatigue flarhea   Government and serversponse rate to GP, fever, downment arthalgia, pain, chills, arthalgia, hadache, intermediate dose 2.0 × 10° diarhea
WVA-BN-Filo   (1 × 10 <sup>8</sup> TCID <sub>30</sub> )   [Kikwit], injection site pain, prexis, puritus (generalized)     rVSVΔG-ZEBOV-   rVSVΔG-ZEBOV-GP (single dose 2 × 10 <sup>7</sup> Vaccine efficacy 5 50% or there was a 2-fold infection risk increase; safety outcome     rVSVΔG-ZEBOV-   rVSVΔG-ZEBOV-   rVSVΔG-ZEBOV-   VSVΔG-ZEBOV-     rVSVΔG-ZEBOV-   rVSVΔG-ZEBOV-   rVSVAG-ZEBOV-   FUN     a 2-fold infection risk increase; safety outcome   a 2-fold infection risk increase; safety outcome     rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-     rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-     GP   2×10 <sup>7</sup> e2-fold infection risk increase; safety outcome     rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-     GP   2×10 <sup>7</sup> e2-fold infection risk increase; safety outcome   rVSVAG-ZEBOV-     rVSVAGT1-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV-   rVSVAG-ZEBOV- </td
rVSVΔG-ZEBOV- NSVΔG-ZEBOV-GP (single dose $2 \times 10^{\circ}$ Vaccine efficacy $\ge 50\%$ or there was GP PFU) a 2-fold infection risk increase; safety outcome rVSVΔG-ZEBOV- rVSVΔG-ZEBOV-GP ELISA positive response rate to GP, PRNT GP 2×10 <sup>7</sup> PFU, actron site High dose $1 \times 10^8$ PFU adverse events, fever, headache, arthralgia, pain, chills, fatigue rVSVNACT1- rVSVNACT1- rVSVNACT1- rVSVNACT1- ELISA positive response rate to GP, fever, teadore, and the adverse events, facer, headache, arthralgia, pain, chills, fatigue low dose $2.5 \times 10^4$ diarrhea diarche advector advector of the advector of
rVSVΔG-ZEBOV- rVSVΔG-ZEBOV-GP GP 2x10 <sup>7</sup> PFU, High dose 1 × 10 <sup>8</sup> PFU rVSVN4CT1- rVSVN4CT1-EBOVGP1 EBOVGP1 2 doses (d0, d28) low dose 2.5 × 10 <sup>6</sup> intermediate dose 2.0 × 10 <sup>5</sup> High dose 1.8x10 <sup>8</sup>
rVSVN4CT1- rVSVN4CT1-EBOVGP1 EBOVGP1 2 doses (d0, d28) low dose 2.5 × 10 <sup>4</sup> intermediate dose 2.0 × 10 <sup>5</sup> High dose 1.8x10 <sup>8</sup>

Ebola vaccious y econocimana supero, y accordance in why system and why system and set in an economic system and set in and set in a material y fift, and Hamburg Ebola vaccious y econocimana system and set in a set in



Number in parentheses are references.

Figure 3. Summary of risk bias assessment for RCTs Ebola vaccines comparisons. Number in parentheses are references.

in supplemental Table S5. As for fatigue, a higher dose  $(10^6 \text{ PFU})$  of rVSVN4CT1-EBOVGP1 vaccine was significantly associated with an increased risk of headache, except for the rVSV $\Delta$ G-ZEBOV-GP vaccine at dose of  $10^7 \text{ PFU}$  (0.03, 0.00–1.13).

The risk of myalgia was assessed in 19 RCTs involving 18 different groups of vaccines and 61 pairwise comparisons. ChAd3 at dose of  $10^{10}$  VP was associated with a lower risk of myalgia (*P*-score 0.94). A total of 26 indirect comparisons were significant, with a 40% to 96% risk reduction of myalgia (Table

S6 in the Supplement). These specific risk reductions were more important for ChAd3 vaccine ( $10^{10}$  VP) compared with rVSV $\Delta$ G-ZEBOV-GP: 92% (0.08, 0.01–0.95) for 2 × 10<sup>7</sup> PFU, 94% (0.06, 0.00–0.98) for 10<sup>7</sup> PFU, 94% (0.06, 0.01–0.73) for 10<sup>6</sup> PFU, 94% (0.06, 0.00–0.65) for 10<sup>8</sup> PFU, and 96% (0.04, 0.00–0.53) for 5 × 10<sup>7</sup> PFU (Figure 5).

For fever, data were available in 19 RCTs with 17 different groups vaccines yielding 57 pairwise comparisons. Ad5-EBOV at dose of  $\leq 8 \times 10^{10}$  was ranked as giving the best results (*P*-score 0.80). This vaccine was associated with a lower risk of

Treatment	Vaccines vs. MVA(10e8)	OR 95%-CI P-Scor	е
rVSVZGP(2dose10e7) Ad26(5dose10e10) rVSVZGP(10e6) rVSVZGP(10e8) ChAd3(10e10) rVSVZGP(10e7) MVA(5dose10e10) rVSVZGP(5dose10e7) rVSVN4CT1(10e5 or lower) rVSVN4CT1(10e6 or higher) DNAEBO(4mg or lower) ChAd3(10e11) Ad5(8dose10e10 or lower) Ad5(1.6dose10e11) rVSVZGP(10e5 or lower) DNAEBO(8mg) MVA(10e8) Placebo		$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6286576637665981
0.01 Decreased chance	0.1 1 10 100 Seroconversion	Increased chance	
	Vaccines vs.		
Treatment	Vaccines vs. Placebo	OR 95%–CI P–Sco	ore
Treatment rVSVZGP(2dose10e7) Ad26(5dose10e10) rVSVZGP(10e6) rVSVZGP(10e8) ChAd3(10e10) rVSVZGP(5dose10e7) rVSVZGP(5dose10e7) rVSVN4CT1(10e5 or lower) rVSVN4CT1(10e6 or higher) DNAEBO(4mg or lower) ChAd3(10e11) Ad5(8dose10e10 or lower) Ad5(1.6dose10e11) rVSVZGP(10e5 or lower) DNAEBO(8mg) MVA(10e8) Placebo		259.12   [134.42; 499.50]   0     285.00   [46.20; 1758.22]   0     218.76   [78.72; 607.94]   0     197.73   [87.45; 447.09]   0     204.64   [29.01; 1443.71]   0     187.58   [31.67; 1110.88]   0     147.22   [16.36; 1325.07]   0     144.16   [37.12; 559.84]   0     140.60   [ 5.86; 3375.64]   0     120.33   [ 4.16; 3481.79]   0     95.15   [ 8.77; 1032.12]   0     113.55   [ 56.23; 229.29]   0     106.75   [ 41.74; 273.04]   0     105.88   [ 41.30; 271.45]   0     93.57   [ 37.19; 235.41]   0     17.39   [ 1.05; 287.12]   0     11.77   [ 1.90; 72.76]   0     1.00   0	.80 .76 .68 .66 .57 .56 .53 .47 .46 .45 .39 .18 .11 .00

Figure 4. Pairwise comparisons in network meta-analysis for immunogenicity.

fever (0.19, 0.06–0.57) compared with ChAd3 vaccine ( $10^{11}$ ). The corresponding specific risk reduction of fever for Ad5-EBOV vaccine ( $8 \times 10^{10}$ ) compared with rVSV $\Delta$ G-ZEBOV-GP were 82% (0.18, 0.06–0.52) for  $10^6$  PFU, 88% (0.12, 0.05–0.30) for  $2 \times 10^7$  PFU, 90% (0.10, 0.03–0.28) for  $10^8$  PFU, and 91% (0.09, 0.02–0.37) for  $5 \times 10^7$  PFU. In addition, ChAd3 ( $10^{11}$ ) and rVSV $\Delta$ G-ZEBOV-GP vaccines ( $10^6$ ,  $2 \times 10^7$ ,  $5 \times 10^7$ , and  $10^8$ ) were associated with more fever than placebo, a lower dose of rVSV $\Delta$ G-ZEBOV-GP vaccine ( $\leq 10^5$ ), and Ad5-EBOV vaccine ( $\leq 8 \times 10^{10}$  and  $1.6 \times 10^{11}$ ) (Table S7 in the Supplement).

The remaining significant comparisons for headache, myalgia, and fever were showed in the Supplement (Table S5 to Table S7).

# Heterogeneity, consistency, and sensitivity

Except for injection-site pain, fatigue, and fever, no general heterogeneity or inconsistency of vaccine effect was found (*P* value greater than 0.05;  $I^2$  ranging from 0% to

Treatment	Vaccines vs. Placebo	OR	95%-CI
Ad26(5dose10e10)			
njection site–Pain <sup>-</sup> atigue		5.32 2.29	[1.52; 18.65] [0.89; 5.85]
Headache		1.67	[0.74; 3.79]
Myalgia		2.25 1.27	[0.88; 5.76]
<sup>-</sup> ever Ad5(1.6dose10e11)		1.27	[0.04; 37.51]
njection site–Pain		7.64	[2.72; 21.52]
Fatigue Headache		2.16 1.39	[0.87; 5.37] [0.75; 2.57]
Viyalgia		1.55	[0.66; 3.60]
<sup>-</sup> ever Ad5(8dose10e10 or lower)		1.52	[0.74; 3.12]
njection site-Pain		3.70	[1.39; 9.89]
Fatigue		1.65 1.13	[0.63; 4.32] [0.59; 2.15]
Headache Myalgia		1.63	[0.64; 4.15]
ever	-	0.90	[0.43; 1.92]
ChAd3(10e10) njection site–Pain		7.73	[1.58; 37.74]
Fatigue	+ <b>e</b> _	2.38	[0.74; 7.70]
Headache Myalgia		3.48 0.22	[1.14; 10.63] [0.02; 2.55]
ever		2.56	[0.40; 16.48]
ChAd3(10e11)		4.00	[1 17: 15:50]
njection site-Pain Fatigue		4.26 2.76	[1.17; 15.58] [1.26; 6.03]
Headache		2.03	[1.28; 3.20]
∕lyalgia Fever		2.02 4.88	[1.46; 2.78] [2.10; 11.31]
DNAEBO(4mg or lower)	-		
njection site-Pain Fatigue		7.29 0.50	[1.14; 46.77] [0.12; 2.17]
Headache		0.68	0.22: 2.14
Viyalgia		0.93	[0.31; 2.81]
<sup>-</sup> ever DNAEBO(8mg)	<b>_</b>	1.68	[0.22; 13.16]
njection site–Pain	<b>-</b>	2.44	[0.19; 31.77]
Headache Myalgia		0.68 5.64	[0.08; 5.70] [0.66; 48.17]
ever		1.72	[0.10; 28.72]
VIVA(10e8)		5.01	[1 04: 00 01]
njection site–Pain <sup>-</sup> atigue		5.31 1.60	[1.24; 22.81] [0.55; 4.61]
Headache	- <b>+</b> _	0.98	[0.39; 2.47]
∕lyalgia Fever		1.90 1.27	[0.67; 5.39] [0.04; 37.51]
WVA(5dose10e10)		1.27	[0.04, 07.01]
njection site-Pain		4.76 1.83	[0.75; 30.19] [0.47; 7.08]
Fatigue Headache		1.65	[0.47; 7.08] [0.52; 5.27]
Myalgia		3.56	[1.07; 11.80]
VSVN4CT1(10e5 or lower) njection site-Pain		6.74	[0.23: 199.21]
Fatigue		2.00	[0.23; 199.21] [0.17; 24.14] [0.17; 83.88]
Headache Myalgia		3.80 1.46	[0.17; 83.88] [0.05; 39.36]
ever		1.46	[0.05; 44.18]
VSVN4CT1(10e6 or higher)		10.00	0.60, 500.641
njection site-Pain Fatigue		- 19.00 - 72.00	[0.60; 599.64] [3.43; 1512.56] [4.22; 3430.21]
Headache		120.33	[4.22; 3430.21]
Myalgia ≂ever		5.59 5.59	[0.23; 133.61] [0.21; 150.60]
VSVZGP(10e5 or lower)			
njection site-Pain	-	1.26 1.77	[0.49; 3.25] [0.94; 3.32]
Fatigue Headache		1.17	[0.74; 1.86]
Viyalgia		1.68	[1.06; 2.66]
Fever VSVZGP(10e6)	<b>—</b>	0.98	[0.44; 2.17]
njection site-Pain		5.86	[2.16; 15.86]
Fatigue Headache	<del></del>	3.12 2.97	[1.62; 6.00] [1.83; 4.80]
Vyalgia		3.59	[2.22; 5.82]
ever		5.09	[2.36; 10.98]
VSVZGP(10e7) njection site–Pain	<b>_</b>	17.09	[1.71; 170.38]
Fatigue	<b>⊢</b> ∎−−	3.46	[0.79; 15.18]
Headache Myalgia		3.83 3.46	[1.10; 13.30] [1.01; 11.93]
Fever	-+	2.61	[0.41; 16.46]
VSVZGP(10e8) njection site–Pain		10.46	[3.63; 30.13]
Fatigue	-■-	4.12	[2.12; 8.02]
Headache		3.06	[1.98; 4.73]
Myalgia Fever		4.04 9.42	[2.54; 6.43] [4.39; 20.20]
VSVZGP(2dose10e7)			
njection site–Pain Fatigue	<b></b>	8.26 3.19	[3.83; 17.80] [1.98; 5.15]
-aligue Headache		2.94	[2.19; 3.97]
Myalgia	<b>₫_</b>	2.68	[2.00; 3.58]
-ever VSVZGP(5dose10e7)	=	7.76	[4.46; 13.49]
njection site-Pain		17.79	[3.74; 84.68]
njection site-i ani		0.05	[0.75; 5.64]
atigue	+∎-	2.05	[1.09: 5.04]
Fatigue Headache Myalgia		2.05 2.45 5.37	[1.08; 5.57] [2.44; 11.82]

0.001 0.1 1 10 1000 Favours for Vaccine Deleterious for Vaccine

**Figure 5.** Pairwise comparisons in network meta-analysis for safety outcomes (injection site-pain, fatigue, headache, myalgia, and fever). OR: odds ratio; CI: 95% confidence interval; **rVSVZGP (10e5 or lower), (10e6), (10e7), (2dose10e7), (5dose10e7), and (10e8)** were the recombinant replication competent vesicular stomatitis virus-based vaccine expressing the glycoprotein of a Zaire Ebolavirus (rVSVΔG-ZEBOV-GP) at doses of  $\leq 10^5$  plaque-forming unit (PFU),  $10^6$  PFU,  $10^7$  PFU,  $2 \times 10^7$  PFU,  $5 \times 10^7$  PFU, and  $10^8$  PFU; **ChAd3 (10e10) and (10e11)** were the replication-defective chimpanzee adenovirus 3 vector expressing Zaire-Ebola virus glycoprotein and other filovirus antigens (MVA-BN-Filo) at doses of  $1 \times 10^8$  50% tissue culture infectious doses (TCID<sub>50</sub>); **Ad5 (8dose10e10 or lower) and (1.6dose10e11)** were the adenovirus type-5 vector-based Ebola vaccine (Ad2-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and  $1.6 \times 10^{11}$  VP; **Ad26 (5dose10e10)** was the adenovirus type-5 vector-based Ebola vaccine (Ad2-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and **1.6 × 10^{11}** VP; **Ad26 (5dose10e10)** was the adenovirus type-5 vector-based Ebola vaccine (Ad2-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and **1.6 × 10^{11}** VP; **Ad26 (5dose10e10)** was the adenovirus type-20 vector-based Ebola vaccine (Ad2-ZEBOV) at doses of  $5 \times 10^{10}$  VP; and **1.6 × 10^{11}** VP; **Ad26 (5dose10e10)** was the vaccine (EBODNA012-00-VP) at doses of 4 mg/ml and 8 mg/ml; **rVSVN4CT1 (10e5 or lower), and (10e6)** were the recombinant replication competent vesicular stomatitis virus-based vaccine expressing HIV-1 gag and glycoprotein of Ebolavirus (rVSVN4CT1-EBOVGP1) at doses of  $2.5 \times 10^4$  PFU,  $2.5 \times 10^5$  PFU, and  $2 \times 10^6$  PFU.

18%). These finding were supported by the heat plot displayed in the Supplemental Figures S4 to S9. In sensitivity analysis, after excluding the nine studies<sup>12-14,19,21,24,27-30</sup> sponsored by the Industrial companies or the seven ones conducted in Africa,<sup>15,17,20,21,26-28</sup> the Ad5.ZEBOV ( $1.6 \times 10^{11}$ ) became the most immunogenic vaccine (*P*-score 0.91 and 0.88, respectively). Finally, after considering only the nine studies with a lower risk of bias,<sup>4,13,15,17,19,21,22,26,31</sup> the rVSV $\Delta$ G-ZEBOV-GP ( $10^8$ ) became the most immunogenic vaccine (*P*-score 0.76).

# Discussion

This study, based on 21 RCTs involving 5,275 healthy volunteers randomly assigned to 18 different groups of candidate vaccines, is the first network meta-analysis of vaccines against Ebola virus. Considering immunogenicity, we found that the rVSV $\Delta$ G-ZEBOV-GP vaccine at the dose of 2 × 10<sup>7</sup> PFU was the most effective available option. These findings support the high protective role of this treatment option to prevent Ebola virus disease, as previously reported from individual phase 1 and/or 2 studies, and data from phase 3 conducted in contacts and contacts of contacts in Guinea (Conakry) and Sierra-Leonne.<sup>3</sup> We found a good overall consistency of the network meta-analysis for immunogenicity.

Despite a rapid immune response, the safety profile of the rVSV $\Delta$ G-ZEBOV-GP vaccine (2 × 10<sup>7</sup>) would be questionable for mass vaccination in the absence of immediate risk of exposure. Compared with others vaccines, we found increased injection site-pain and fever reported by patients who received a single dose of this vaccine. These findings are in lines with those reported in Ebola ca Suffit trial where 80 serious adverse events were identified, of which two were judged to be related to vaccination (one febrile reaction and one anaphylaxis). A high reactogenicity may increases vaccine hesitancy, especially in Africa where unfavorable socioeconomic factors, low level of health education, lack of disease awareness, religious and cultural beliefs may decrease vaccination uptake. Future studies should be conducted in African populations that have experienced Ebola disease to investigate risk factors and barriers to vaccination.

In the sensitivity analysis, we found a substantial change in vaccines effect estimates from those seen in the overall network meta-analysis for immunogenicity. When excluding studies sponsored by the industry companies<sup>12–</sup> <sup>14,19,21,24,27–30</sup> or those conducted elsewhere other than Africa area, <sup>15,17,20,21,26–28</sup> the Ad5.ZEBOV ( $1.6 \times 10^{11}$  VP) became the most immunogenic vaccine, suggesting that Ad26.ZEBOV might be a possible alternative vaccine. Compared to placebo, the Ad26.ZEBOV vaccine gives the highest immunogenic level, and was associated with a lower rate of reactogenicity. Moreover, no difference in terms of risk difference (0.04 [95% CI; -0.13 to 0.20]) were observed as compared to the rVSV $\Delta$ G-ZEBOV-GP ( $2 \times 10^7$ ) vaccine. Pending the results of a large randomized trial between these two vaccines, we recommend to use the Ad26. ZEBOV (5  $\times$  10<sup>10</sup> VP) vaccine with an MVA boost in cases of contraindication or limited availability of the rVSV $\Delta$ G-ZEBOV-GP (2 × 10<sup>7</sup>) vaccine to stop future outbreak of Ebola. However, in both indirect comparisons, the precision (95% CI) of vaccine effect estimates for Ad26. ZEBOV (1.6  $\times$  10<sup>11</sup>) compared with rVSV $\Delta$ G-ZEBOV-GP  $(2 \times 10^7)$  is high, reflecting the relatively small number of participants contributing to the network meta-analysis. The rVSV $\Delta$ G-ZEBOV-GP vaccine (2 × 10<sup>7</sup>) ranked 4<sup>th</sup> out of 15 groups of vaccines and 5<sup>th</sup> out of 17 groups of vaccines, respectively (sensitives analyses). In addition, after taking into account only studies with a low risk of bias, the rVSV $\Delta$ G-ZEBOV-GP (10<sup>8</sup>) become the most immunogenic vaccine, while the same vaccine at dose of  $2 \times 10^7$  was ranked 3<sup>th</sup> out of 14 groups of treatments. Nevertheless, these sensitivity analyses were performed on a small number of RCTs with few participants which may have reduced the power of the test.

Some limitations were present in this study. First, the classification used to define these 18 groups of vaccines for comparisons is disputable, and possibly other categorization would result in different conclusions. In addition, the conclusions of the overall network analysis differ substantially from those of the sensitivity analyses, mainly after exclusion of studies sponsored by industrial companies or those conducted outside Africa, suggesting caution in interpretating the data. Second, the different ELISA assays methods and the different thresholds used to define seroconversion rates for immunogenicity may influence the results of the efficacy analysis. Standardized methods would be preferable in order to improve the conclusion in future studies.<sup>32</sup> An alternative approach to the use of a single time point of ELISA data would be to focus on peak titers regardless of time point, although neglecting the value of the onset of protection is a problem with this method. Third, the use as a single time-point of the outcome analysis, 28-day after single immunization which limits the ability to assess immunogenicity of Ebola vaccines of more than one dose regimen. Moreover, the methods of comparing vaccines with different immunization regimens in a network metaanalysis remains an open question due to transitivity requirement. Finally, as the search was restricted to English language trials, a residual publication bias is possible despite our effort to locate unpublished trials through ClinicalTrial.gov. Nevertheless, Jüni Peter et al. suggest that bias induces by excluding non-language English trials has only modest effects on aggregated treatment effect estimates.<sup>33</sup>

Our findings suggest that the rVSV $\Delta$ G-ZEBOV-GP vaccine with dose of 2 × 10<sup>7</sup> has the strongest evidence for being the most effective vaccine in terms of immunogenicity to prevent the next outbreak of Ebola virus disease. These findings have implications on the design of future clinical trials, and management of the next outbreak of Ebola Virus Disease. Future large prospective RCTs are needed to draw final conclusions.

# **Abbreviations**

RCT rVSV∆G-ZEBOV- GP	based vaccine expressing the glycoprotein of a Zaire
ChAd3-EBO-Z	Ebolavirus replication-defective chimpanzee adenovirus 3 vector expressing Zaire-Ebola virus glycoprotein
MVA-BN-Filo	modified vaccinia Ankara (MVA) expressing Zaire Ebola virus glycoprotein and other filovirus antigens
Ad5.ZEBOV	adenovirus type-5 vector-based Ebola vaccine
Ad26.ZEBOV	adenovirus type-26 vector-based Ebola vaccine
EBODNA012- 00-VP	Ebola virus glycoprotein DNA vaccine
ELISA	enzyme-linked immunosorbent assay
PFU	plaque-forming unit
TCID <sub>50</sub>	50% tissue culture infectious doses
VP	viral particles
NR	not reported.

# **Disclosure of potential conflicts of interest**

We declare no competing interests in relation to this work.

# ORCID

Alhassane Diallo (D) http://orcid.org/0000-0002-1666-8641

# **Author contributions**

ADi conceived the study design, analyzed the data, and drafted the manuscript, MCB supervision of data collection, and critical revision of the manuscript, VW collected data, MHD analyzed the data, BDD, AD, MCG, and FG interpreted and substantially revised the manuscript. All authors approved the final version of the manuscript.

# Availability of data and materials

The data are available upon request (alhassane.diallo@inserm.fr).

# References

- 1. WHO: Ebola virus disease [situation report] Geneva, Switzerland: World Health Organization; 2016http://apps.who.int/ebola/ebolasituation-reports.
- Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK, et al. Human adaptation of Ebola virus during the West African outbreak. Cell. 2016;167:1079–1087.e5. doi:10.1016/j. cell.2016.10.013.
- Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–18. doi:10.1016/ S0140-6736(16)32621-6.
- 4. Heppner D, Kemp T, Martin B, Ramsey W, Nichols R, Dasen E, Link CJ, Das R, Xu ZJ, Sheldon EA, et al. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17:854-866. doi:10.1016/S1473-3099(17)30313-4.
- Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus

disease therapeutics. N Engl J Med. 2019;381:2293-303. doi:10.1056/NEJMoa1910993.

- Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines. 2016;15:1101–12. doi:10.1080/14760584.2016.1187566.
- Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F. Ebola vaccines in clinical trial: the promising candidates. Hum Vaccines Immunother. 2017;13:153–68. doi:10.1080/21645515.2016.1225637.
- U.S. Department of Health and Human Services National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0. 2017 Nov 27.
- Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928. doi:10.1136/bmj. d5928.
- Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R. Springer International Publishing; 2015. p. 252.
- Martin J, Sullivan N, Enama M, Gordon I, Roederer M, Koup R, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267-1277. doi:10.1128/CVI.00162-06.
- 12. Ledgerwood J, Costner P, Desai N, Holman L, Enama M, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304-313. doi:10.1016/j.vaccine.2010.10.037.
- Zhu F-C, Hou L-H, Li J-X, Wu S-P, Liu P, Zhang G-R, Hu Y-M, Meng F-Y, Xu -J-J, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385:2272–79. doi:10.1016/S0140-6736(15)60553-0.
- 14. Huttner A, Dayer J, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156-1166. doi:10.1016/S1473-3099(15)00154-1.
- 15. Kibuuka H, Berkowitz N, Millard M, Enama M, Tindikahwa A, Sekiziyivu A, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet Lond Engl. 2015;385:1545-1554.
- Agnandji S, Huttner A, Zinser M, Njuguna P, Dahlke C, Fernandes J, Yerly S, Dayer J-A, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647-1660. doi:10.1056/NEJMoa1502924.
- 17. Tapia M, Sow S, Lyke K, Haidara F, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31-42.
- De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311-320. doi:10.1016/S1473-3099(15)00486-7.
- Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and immunogenicity of novel adenovirus type 26and modified vaccinia ankara-vectored Ebola vaccines:

a randomized clinical trial. JAMA. 2016;315:1610-1623. doi:10.1001/jama.2016.4218.

- 20. Agnandji S, Fernandes J, Bache E, Obiang Mba R, Brosnahan J, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, et al. Safety and immunogenicity of rVSVDELTAG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial. Plos Med. 2017;14. doi:10.1371/journal.pmed.1002402.
- 21. Zhu F, Wurie A, Hou L, Liang Q, Li Y, Russell J, Wu SP, Li JX, Hu YM, Guo Q, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2017;389:621-628.
- 22. Kennedy S, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438-1447. doi:10.1056/NEJMoa1614067.
- 23. ElSherif M, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ Can Med Assoc J. 2017;189:E819-E827. doi:10.1503/cmaj.170074.
- 24. Li J, Hou L, Meng F, Wu S, Hu Y, Liang Q, Chu K, Zhang Z, Xu -J-J, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324-e334. doi:10.1016/S2214-109X (16)30367-9.
- Regules J, Beigel J, Paolino K, Voell J, Castellano A, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376:330-341. doi:10.1056/NEJMoa1414216.
- 26. Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M. Safety and Immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J Infect Dis. 2019;220:57-67. doi:10.1093/infdis/jiz071.

- 27. Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J Infect Dis. 2019;220(1):46-56. doi:10.1093/infdis/jiz070.
- 28. Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, et al. The Sierra Leone trial to induce a vaccine against Ebola: an evaluation of rVSV $\Delta$ G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis. 2018;217:S6-15. doi:10.1093/infdis/jiy020.
- 29. Halperin SA, Arribas JR, Andrews CP, Chu L, Das R, Simon JK, Simon JK, Onorato MT, Liu K, Martin J, et al. Six-month safety data of recombinant vesicular stomatitis virus ebola envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215:1789-98. doi:10.1093/infdis/jix189.
- 30. Halperin SA, Das R, Onorato MT, Lui K, Martin J, Grant-Klein R, Nichols R, Coller B-A, Helmond FA, Simon JK, et al. Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 double-blind, placebocontrolled randomized study in healthy adults. J Infect Dis. 2019;220:1127-35. doi:10.1093/infdis/jiz241.
- 31. Clark DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi C, Luckay A, Witko SE, Hermida L, Higgins T, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccines: a randomized double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020;20:455-66.
- 32. Niemuth NA, Rudge TL Jr, Sankovich KA, Anderson MS, Skomrock ND, Badorrek CS, Sabourin CL. Method feasibility for cross-species testing, qualification, and validation of the Filovirus animal nonclinical group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. Plos ONE. 2020;15(10):e0241016. doi:10.1371/journal.pone.0241016.
- Jüni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analysis of controlled trials: empirical study. Int J Epidemiol. 2002;31:115–23. doi:10.1093/ije/ 31.1.115.